{"id":"NCT04590586","sponsor":"Amgen","briefTitle":"Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients","officialTitle":"Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-24","primaryCompletion":"2021-08-03","completion":"2021-08-03","firstPosted":"2020-10-19","resultsPosted":"2022-06-29","lastUpdate":"2022-06-29"},"enrollment":515,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Standard of care","otherNames":[]},{"type":"DRUG","name":"Apremilast","otherNames":["Otezla"]},{"type":"DRUG","name":"Apremilast placebo","otherNames":[]},{"type":"DRUG","name":"Lanadelumab","otherNames":["TAKHZYROâ„¢","TAK-743"]},{"type":"DRUG","name":"Lanadelumab placebo","otherNames":[]},{"type":"DRUG","name":"Zilucoplan","otherNames":[]},{"type":"DRUG","name":"Zilucoplan placebo","otherNames":[]}],"arms":[{"label":"Apremilast + Standard of Care","type":"EXPERIMENTAL"},{"label":"Apremilast Placebo + Standard of Care","type":"PLACEBO_COMPARATOR"},{"label":"Lanadelumab + Standard of Care","type":"EXPERIMENTAL"},{"label":"Lanadelumab Placebo + Standard of Care","type":"PLACEBO_COMPARATOR"},{"label":"Zilucoplan + Standard of Care","type":"EXPERIMENTAL"},{"label":"Zilucoplan Placebo + Standard of Care","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.","primaryOutcome":{"measure":"Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29","timeFrame":"Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29","effectByArm":[{"arm":"Lanadelumab + Standard of Care","deltaMin":10,"sd":null},{"arm":"Lanadelumab Placebo Control","deltaMin":15.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6672"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":16},"locations":{"siteCount":59,"countries":["United States","Argentina","Brazil","Chile","Mexico","Russia","South Africa","Ukraine"]},"refs":{"pmids":["34473343"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":27},"commonTop":["Constipation","Hypotension","Hypertension","Anaemia","Pyrexia"]}}